Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL5445950 | 0.90 | KDM4E (0.36) | KDM4EATMPOLBMAPK1KCNH2 | |
| Hydrochloric Acid SCHEMBL5444909 | 0.89 | KDM4E (0.32) | KDM4EATMPOLBMAPK1 | |
| Bromide SCHEMBL5445824 | 0.89 | KDM4E (0.32) | KDM4EATMPOLBMAPK1 | |
| SCHEMBL5442180 | 0.88 | KDM4E (0.31) | KDM4EATMPOLBMAPK1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5445998 | 0.79 | ACHE (0.34) | KDM4ENPSR1RXFP1 | |
| Bromide SCHEMBL5439305 | 0.78 | KDM4E (0.33) | KDM4EATMPOLBMAPK1 | |
| Hydrochloric Acid SCHEMBL5439269 | 0.78 | KDM4E (0.33) | KDM4EATMPOLBMAPK1 | |
| SCHEMBL5449885 | 0.78 | KDM4E (0.32) | KDM4EATMPOLBMAPK1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5447746 | 0.77 | KCNH2 (0.31) | KCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL5446071 | 0.76 | KCNH2 (0.35) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1658297-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005016940-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | KDM4E 1831/4885ATM 4255/4885POLB 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.